Analyst Price Targets — STRO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 14, 2025 1:19 pm | — | Piper Sandler | $20.00 | $8.10 | TheFly | Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler |
| October 11, 2024 7:01 am | Tazeen Ahmad | Bank of America Securities | $120.00 | $36.05 | StreetInsider | BofA Securities Reiterates Buy Rating on Sutro Biopharma (STRO) |
| October 11, 2024 6:36 am | Andrew Fein | H.C. Wainwright | $120.00 | $36.10 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Sutro Biopharma (STRO) |
| August 16, 2024 6:58 am | Asthika Goonewardene | Truist Financial | $150.00 | $42.10 | StreetInsider | Sutro Biopharma (STRO) PT Lowered to $15 at Truist Securities |
| May 14, 2024 4:12 pm | James Shin | Deutsche Bank | $100.00 | $43.40 | StreetInsider | Sutro Biopharma (STRO) PT Lowered to $10 at Deutsche Bank |
| May 14, 2024 8:25 am | David Nierengarten | Wedbush | $80.00 | $42.30 | StreetInsider | Wedbush Reiterates Outperform Rating on Sutro Biopharma (STRO) |
| April 3, 2024 2:01 pm | Jay Olson | Oppenheimer | $100.00 | $50.90 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Sutro Biopharma (STRO) |
| April 3, 2024 6:48 am | Edward Tenthoff | Piper Sandler | $110.00 | $50.90 | StreetInsider | Sutro Biopharma (STRO) PT Lowered to $11 at Piper Sandler |
| April 2, 2024 4:12 pm | Asthika Goonewardene | Truist Financial | $180.00 | $50.90 | StreetInsider | Sutro Biopharma (STRO) PT Lowered to $18 at Truist Securities |
| January 13, 2023 8:27 am | — | Truist Financial | $250.00 | $81.35 | Benzinga | Truist Securities Maintains Buy on Sutro Biopharma, Raises Price Target to $25 |
Latest News for STRO
STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful, dose-dependent antitumor activity across solid tumor models Presentation of TROP2-targeted immunostimulatory ADC program partnered with Astellas highlights the potential of Sutro's platform for developing dual-payload…
Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report)'s stock price traded up 10.4% on Friday after Citizens Jmp raised their price target on the stock from $23.00 to $35.00. Citizens Jmp currently has a market outperform rating on the stock. Sutro Biopharma traded as high as $32.58 and last traded at $32.3910. 120,254 shares traded
Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 –
Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report) has been given an average recommendation of "Hold" by the nine ratings firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and four have issued a buy recommendation on
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for STRO.
U.S. House Trading
No House trades found for STRO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.